The failure of HARRT to cure the HIV-1/AIDS complex.: Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations.

被引:7
作者
Mathé, G
机构
[1] Inst Cancerol & Immunol, F-92133 Issy Les Moulineaux, France
[2] Hop Suisse Paris, F-92133 Issy Les Moulineaux, France
关键词
drug rotation; ellipticine acriflavine; HAART; integrase inhibitors;
D O I
10.1016/S0753-3322(01)00074-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
While the intensive virostatic combinations applied according to the conventional models (such as HAART), based only on the attacks of two HIV-1 targets, retrotranscriptase and protease, and applied in a long and continuous fashion, a) are notably toxic, b) do not correct completely the abnormal immunologic parameters, and c) are followed by particularly severe and poorly sensitive relapses in case of discontinuation, we propose to the 'AIDS treatment headquarters' to include in their failing strategy the two original features which we have included in the treatment of a cohort of a dozen patients, treatment applied at all but one AIDS stage. We attack one more HIV-I target than the conventional protocols do, by adding inhibitors of integrase; we apply the combinations of virostatics, comprising inhibitors of the three targets, in short sequences (of 3 weeks), between which the analogues are changed inside each series. The first patient of the cohort started his treatment 8.5 years ago, and the entries of the others into it have been at random and not randomized. All patients are alive today and in excellent concition. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:295 / 300
页数:6
相关论文
共 41 条
[1]  
Assinder EW, 1936, LANCET, V1, P304
[2]   VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
BORROW, P ;
LEWICKI, H ;
HAHN, BH ;
SHAW, GM ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110
[3]  
BOYD ML, 1930, UROL CUTAN REV, V34, P303
[4]   Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection [J].
Colven, R ;
Harrington, RD ;
Spach, DH ;
Cohen, CJ ;
Hooton, TM .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :430-434
[5]   A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents [J].
Cushion, MT ;
Chen, F ;
Kloepfer, N .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :379-384
[6]   Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion [J].
Daar, ES ;
Bai, JX ;
Hausner, MA ;
Majchrowicz, M ;
Tamaddon, M ;
Giorgi, JV .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (10) :827-829
[7]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[8]  
Ellenberg S S, 1992, Oncology (Williston Park), V6, P55
[9]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
[10]  
Freireich Emil J., 1997, P2966